This is a scientific update with no near-term commercial or regulatory catalyst. Monitor for any subsequent announcement of a larger controlled trial in Alzheimer's, which would be the next meaningful de-risking event. The existing 20-F (April 2026) showed strong revenue growth of 27% to $52.2M, that fundamental trajectory is the primary driver, not this pilot data.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 8 $14.16entry
- T+1 · 2mo ago +1.77%α +2.23% · $14.41
- T+5 · 2mo ago −3.74%α −3.08% · $13.63
- T+20 · 6w ago −16.03%α −18.00% · $11.89
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and Neurology showing Deep TMS achieved an 83.3% response rate and 50% remission rate for depressive symptoms in patients with comorbid MDD and early-stage Alzheimer's disease, alongside measurable neurophysiological changes. This is an early-stage, hypothesis-generating result in a new indication (Alzheimer's) for which Deep TMS is not FDA-cleared, requiring additional controlled trials before any commercial pathway. The filing is a routine scientific update with no financial data, no regulatory submission, and no change to the company's existing three FDA-cleared indications, making it a modest positive signal for the platform's optionality but not a near-term catalyst.
Key Facts
- Pilot study (n=12) published in peer-reviewed Journal of Geriatric Psychiatry and Neurology
- 83.3% response rate and 50% remission rate for depressive symptoms in patients with MDD and early-stage Alzheimer's
- Deep TMS is NOT FDA-cleared for Alzheimer's disease; additional controlled research required
- Study used H1 and H7 coils; observed QEEG changes in delta power and alpha coherence
- No financial figures, guidance, or regulatory milestones reported in this filing
Financial Impact
No financial impact reported; pilot study is early-stage research with no revenue or cost implications disclosed
Risk Factors
- Pilot study has very small sample size (n=12) and no control arm, limiting generalizability
- Deep TMS is not FDA-cleared for Alzheimer's; path to clearance requires large, expensive pivotal trials with uncertain outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005912 |
| Document: f6k_090626.htm | 0001171843-26-005912 |
| Document: 0001171843-26-005912-index-headers.html | 0001171843-26-005912 |
| Document: 0001171843-26-005912-index.html | 0001171843-26-005912 |
| Document: 0001171843-26-005912.txt | 0001171843-26-005912 |
Track record
24 reports on BWAY
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Viewing Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers